These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 27774018)

  • 1. Partial response to proton pump inhibitor therapy for GERD: observational study of patient characteristics, burden of disease, and costs in the USA.
    Stålhammar NO; Spiegel BM; Granstedt Löfman H; Karlsson M; Wahlqvist P; Næsdal J; Nelson MT; Despiégel N
    Pragmat Obs Res; 2012; 3():57-67. PubMed ID: 27774018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France.
    Bruley des Varannes S; Löfman HG; Karlsson M; Wahlqvist P; Ruth M; Furstnau ML; Despiégel N; Stålhammar NO
    BMC Gastroenterol; 2013 Feb; 13():39. PubMed ID: 23448382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open access capture of patients with gastroesophageal reflux disease using an online patient-reported outcomes instrument.
    Tielemans MM; Jansen JB; van Oijen MG
    Interact J Med Res; 2012 Sep; 1(2):e7. PubMed ID: 23611985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany.
    Gross M; Beckenbauer U; Burkowitz J; Walther H; Brueggenjuergen B
    Eur J Med Res; 2010 Mar; 15(3):124-30. PubMed ID: 20452898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease.
    Rodríguez L; Rodriguez P; Gómez B; Ayala JC; Oxenberg D; Perez-Castilla A; Netto MG; Soffer E; Boscardin WJ; Crowell MD
    Surgery; 2015 Mar; 157(3):556-67. PubMed ID: 25726315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy.
    Mody R; Eisenberg D; Hou L; Kamat S; Singer J; Gerson LB
    Clinicoecon Outcomes Res; 2013; 5():161-9. PubMed ID: 23637544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-specific cost savings of treating nighttime versus daytime gastroesophageal reflux disease in an employed population.
    Doan QV; Lange SM; Elfant A; Aguilar D; Reyes E; Lynn RB; Dubois RW
    J Med Econ; 2008; 11(1):23-40. PubMed ID: 19450108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
    Gosselin A; Luo R; Lohoues H; Toy E; Lewis B; Crawley J; Duh MS
    Value Health; 2009; 12(1):34-9. PubMed ID: 19895371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term benefit of transoral incisionless fundoplication using the esophyx device for the management of gastroesophageal reflux disease responsive to medical therapy.
    Stefanidis G; Viazis N; Kotsikoros N; Tsoukalas N; Lala E; Theocharis L; Fassaris A; Manolakopoulos S
    Dis Esophagus; 2017 Feb; 30(3):1-8. PubMed ID: 27868281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
    Abdallah J; George N; Yamasaki T; Ganocy S; Fass R
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1073-1080.e1. PubMed ID: 29913281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of electrical stimulation of the lower esophageal sphincter in gastroesophageal reflux disease patients refractory to proton pump inhibitors.
    Soffer E; Rodríguez L; Rodriguez P; Gómez B; Neto MG; Crowell MD
    World J Gastrointest Pharmacol Ther; 2016 Feb; 7(1):145-55. PubMed ID: 26855821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
    Foocharoen C; Chunlertrith K; Mairiang P; Mahakkanukrauh A; Suwannaroj S; Namvijit S; Wantha O; Nanagara R
    Rheumatology (Oxford); 2017 Feb; 56(2):214-222. PubMed ID: 27179107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.
    Isshi K; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Ogawa M; Arihiro S; Haruma K; Nakada K
    J Gastroenterol; 2019 Jun; 54(6):492-500. PubMed ID: 30673836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vonoprazan 10 mg daily is effective for the treatment of patients with proton pump inhibitor-resistant gastroesophageal reflux disease.
    Shinozaki S; Osawa H; Hayashi Y; Sakamoto H; Kobayashi Y; Lefor AK; Yamamoto H
    Biomed Rep; 2017 Sep; 7(3):231-235. PubMed ID: 28894571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction?].
    Labenz J; Labenz G; Stephan D; Willeke F;
    MMW Fortschr Med; 2016 May; 158 Suppl 4():7-11. PubMed ID: 27221555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.